Immunovant, Inc.

Equities

IMVT

US45258J1025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-13 EDT			5-day change	1st Jan Change
29.88 ^USD	+1.67%		+0.71%	-29.08%

04-20	Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	MT
04-20	Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	MT

Immunovant, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023

November 09, 2023 at 07:13 am

Immunovant, Inc. reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported net loss was USD 58.66 million compared to USD 47.93 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.41 a year ago.
For the six months, net loss was USD 132.6 million compared to USD 88.3 million a year ago. Basic loss per share from continuing operations was USD 1.01 compared to USD 0.76 a year ago.

Latest news about Immunovant, Inc.

Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	04-19	MT
Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	04-19	MT
Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target	03-28	MT
Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target	03-13	MT
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing	02-23	MT
JPMorgan Starts Coverage on Immunovant With Overweight Rating, $51 Price Target	02-20	MT
Wolfe Research Starts Immunovant With Outperform Rating, $55 Price Target	02-15	MT
Immunovant Posts Narrower Fiscal Q3 Loss	02-12	MT
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
North American Morning Briefing : Stock Futures -2-	02-09	DJ
North American Morning Briefing : Jobs Report Tops -2-	02-02	DJ
Immunovant Insider Sold Shares Worth $383,012, According to a Recent SEC Filing	01-29	MT
Transcript : Immunovant, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM	01-09
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	12-21	MT
HC Wainwright Adjusts Price Target on Immunovant to $51 From $47, Keeps Buy Rating	12-21	MT
Immunovant Gets Positive Data From Graves' Disease Treatment Trial	12-20	DJ
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours	12-20	MT
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates	12-20	CI
Top Premarket Decliners	12-20	MT
Deutsche Bank Initiates Coverage on Immunovant With Buy Rating, $50 Price Target	12-12	MT
Immunovant Insider Sold Shares Worth $490,697, According to a Recent SEC Filing	12-05	MT
Immunovant Insider Sold Shares Worth $504,567, According to a Recent SEC Filing	12-05	MT
Immunovant Insider Sold Shares Worth $490,668, According to a Recent SEC Filing	12-05	MT
UBS Raises Immunovant Price Target to $56 From $55, Maintains Buy Rating	12-01	MT
Sector Update: Health Care Stocks Decline Premarket Tuesday	11-28	MT

Chart Immunovant, Inc.

Duration

Period

More charts

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab (IMVT-1401), and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Gravesâ disease (GD). IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn. IMVT-1402 has also been observed in nonclinical studies to reduce IgG antibody levels. IMVT-1402 is delivered as a 2 mL simple subcutaneous injection.

Sector

Biotechnology & Medical Research

Calendar

2024-06-30 - Q4 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.88 USD

Average target price

50.43 USD

Spread / Average Target

+68.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUNOVANT, INC.	-29.08%	4.27B
MODERNA, INC.	+26.37%	44.96B
IQVIA HOLDINGS INC.	-1.01%	42.65B
LONZA GROUP AG	+46.00%	41.85B
CELLTRION, INC.	-5.31%	29.04B
ICON PUBLIC LIMITED COMPANY	+9.34%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	19.03B
BIO-TECHNE CORPORATION	+6.23%	12.75B
MEDPACE HOLDINGS, INC.	+26.99%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.75B

Other Biotechnology & Medical Research